Zenith Drugs logo

Zenith Drugs financials and balance sheet

NSE: ZENITHDRUGPharmaceuticals & Biotechnology

Last close ₹39.45up ₹1.25 (3.27%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹38.20.

52-week range of traded prices to 23 Oct 2026
₹33.30Low, 30 Mar 2026₹65.50High, 24 Oct 2025
Market cap
₹68 Cr
P/E
17.2
P/B
0.9
Dividend yield
Nonein the last 12 months
ROE
5.5%
Debt to equity
0.75
Volume, NSE
3,20075.0% delivered

3 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Zenith Drugs annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹171 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue171
  2. Depreciation−6.0
  3. Other income+5.1
  4. Finance costs−5.6
  5. Profit before tax5.4
  6. Tax−1.4
  7. Net profit3.9

What the company owns

  • Receivables₹73 Cr
  • Plant, investments and other assets₹71 Cr
  • Inventory₹42 Cr
  • Cash and bank₹0 Cr

What pays for it: net worth and liabilities

  • Net worth₹73 Cr
  • Owed to suppliers₹56 Cr
  • Borrowings₹55 Cr
  • Other liabilities₹4 Cr

Profit and loss

Standalone, ₹ crore, years to March.Zenith Drugs half-yearly results

₹ croreMar 2024Mar 2025Filed 2 JulMar 2026Filed 15 Jun
Revenue from operations132133171
115––
Materials and goods bought8687123
Employee costs6––
Other expenses23––
Operating profit before depreciation17––
Operating margin12.9%––
Materials, % of revenue65.0%––
Employee costs, % of revenue4.6%––
Other expenses, % of revenue17.6%––
Depreciation and amortisation136
Operating profit after depreciation16––
Other income235
Finance costs346
Profit before one-off items and tax15106
One-off items−1––
Profit before tax1395
421
Net profit1074
Net margin7.2%5.4%2.3%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2025 and Mar 2026: revenue, other income and exceptional items less the total expenses stated do not come to the profit before tax the same statement states, so the operating expenses cannot be told apart from the rest.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2025Filed 2 JulMar 2026Filed 15 Jun
6973
Share capital1717
Reserves5256
4955
7994
Liabilities due after a year1320
Total assets161188
4659
115129
Net debt4855
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2025Filed 2 JulMar 2026Filed 15 Jun
−5.58.9
0.316.3
−15.6−0.9
Receivables6.8−12.8
Inventories−13.9−2.8
Payables−4.515.6
Other working capital−4.1−0.9
Tax paid−2.0−1.6
Interest paid0.0−5.6
Capital spending0.09.7
Free cash flow−5.5−0.8
−31.4−13.7
28.44.8
Dividends paid–0.0
Shares issued0.00.0
Net change in cash−8.50.0
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the year to Mar 2024. Dividends paid is left blank for the year to Mar 2025: the cash-flow statement states no dividends paid, while the company's own dividend record shows one paid in the period, so the line is not given.

Per share

Standalone, ₹ per share, years to March.Zenith Drugs dividend history

₹ per shareMar 2024Mar 2025Filed 2 JulMar 2026Filed 15 Jun
Earnings per share–₹4.18₹2.30
Diluted earnings per share–₹4.18₹2.30
Dividend per share₹0.50––
Book value per share–₹40.46₹42.76
Dividend payout9.0%––
Shareholder yield––0.0%
Market cap at the year end (₹ crore)10812360
Shareholder yield is left blank for the year to Mar 2025: the cash-flow statement states no dividends paid, while the company's own dividend record shows one paid in the period, so the line is not given.

Ratios

Standalone, years to March.Zenith Drugs PE ratio and valuation

RatioMar 2024Mar 2025Filed 2 JulMar 2026Filed 15 Jun
Revenue growth–1.3%28.4%
Net profit growth–−24.9%−44.9%
Earnings per share growth––−45.0%
–10.3%5.5%
––−4.8 pts
From the net margin––−5.9 pts
From asset turnover––0.8 pts
From borrowing––0.3 pts
Cash conversion–−76.3%225.2%
Interest cover5.2––
Debt to equity–0.700.75
Receivable days–166156
Inventory days–165126
Payable days–168166
Cash conversion cycle, days–163117
Working capital days–195148
Asset turnover–0.830.98
Assets per rupee of net worth–2.332.45
Sales per rupee of plant–3.334.62
Capital spending to depreciation–0.001.61
No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
2.3%
Measure3 years
Return on equity, average7.9%
Net margin, average5.0%
Asset turnover, average0.90
Cash conversion cycle, days, average140
Debt to equity, average0.73

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations8.9
Cash from investing−13.7
Cash from financing4.8
Capital spending9.7
Dividends paid0.0
Shares issued for cash0.0
Borrowings raised7.3
Borrowings repaid0.8

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points–−7.33
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−33.00
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−1.05
Effective tax ratePublished threshold 17.16 per cent22.6826.82
Tax charged less tax paid, % of profitOur threshold 10 percentage points0.58−3.04
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
8 Sep 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesShort-term scaleCrisil A4+Rating Migrated15.11
8 Sep 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesLong-term scaleCrisil BB+Rating MigratedStable35
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.